129 related articles for article (PubMed ID: 37638828)
41. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
[TBL] [Abstract][Full Text] [Related]
42. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
43. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
44. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Schöffski P; Wozniak A; Leahy MG; Aamdal S; Rutkowski P; Bauer S; Richter S; Grünwald V; Debiec-Rychter M; Sciot R; Geoerger B; Marréaud S; Collette S; Nzokirantevye A; Strauss SJ
Eur J Cancer; 2018 May; 94():156-167. PubMed ID: 29567632
[TBL] [Abstract][Full Text] [Related]
45. [Alveolar rhabdomyosarcoma: novel surrogate markers associated with oncogenic translocation].
Tarakanova AV; Sharlay AS; Konovalov DM
Arkh Patol; 2023; 85(1):10-15. PubMed ID: 36785957
[TBL] [Abstract][Full Text] [Related]
46. Sphingosine Induces Apoptosis and Down-regulation of
Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K
Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758
[TBL] [Abstract][Full Text] [Related]
47. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma.
Lacey A; Hedrick E; Cheng Y; Mohankumar K; Warren M; Safe S
Mol Cancer Ther; 2018 Dec; 17(12):2756-2766. PubMed ID: 30190424
[TBL] [Abstract][Full Text] [Related]
48. Molecular biology of rhabdomyosarcoma.
Gallego Melcón S; Sánchez de Toledo Codina J
Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
[TBL] [Abstract][Full Text] [Related]
49. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
50. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
[TBL] [Abstract][Full Text] [Related]
51. Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature.
Balogh P; Bánusz R; Csóka M; Váradi Z; Varga E; Sápi Z
Diagn Pathol; 2016 Oct; 11(1):99. PubMed ID: 27756397
[TBL] [Abstract][Full Text] [Related]
52. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.
Rengaswamy V; Zimmer D; Süss R; Rössler J
J Control Release; 2016 Aug; 235():319-327. PubMed ID: 27261335
[TBL] [Abstract][Full Text] [Related]
53. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.
Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R
Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298
[TBL] [Abstract][Full Text] [Related]
54. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
[TBL] [Abstract][Full Text] [Related]
55. PAX3-FOXO1: Zooming in on an "undruggable" target.
Wachtel M; Schäfer BW
Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.
Dorado García H; Pusch F; Bei Y; von Stebut J; Ibáñez G; Guillan K; Imami K; Gürgen D; Rolff J; Helmsauer K; Meyer-Liesener S; Timme N; Bardinet V; Chamorro González R; MacArthur IC; Chen CY; Schulz J; Wengner AM; Furth C; Lala B; Eggert A; Seifert G; Hundsoerfer P; Kirchner M; Mertins P; Selbach M; Lissat A; Dubois F; Horst D; Schulte JH; Spuler S; You D; Dela Cruz F; Kung AL; Haase K; DiVirgilio M; Scheer M; Ortiz MV; Henssen AG
Nat Commun; 2022 Jul; 13(1):4297. PubMed ID: 35879366
[TBL] [Abstract][Full Text] [Related]
57. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
58. The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.
Thway K; Wang J; Wren D; Dainton M; Gonzalez D; Swansbury J; Fisher C
Virchows Arch; 2015 Aug; 467(2):217-24. PubMed ID: 25912319
[TBL] [Abstract][Full Text] [Related]
59. Cyclin-dependent kinase 4 phosphorylates and positively regulates PAX3-FOXO1 in human alveolar rhabdomyosarcoma cells.
Liu L; Wu J; Ong SS; Chen T
PLoS One; 2013; 8(2):e58193. PubMed ID: 23469153
[TBL] [Abstract][Full Text] [Related]
60. Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs.
Manceau L; Richard Albert J; Lollini PL; Greenberg MVC; Gilardi-Hebenstreit P; Ribes V
PLoS Genet; 2022 May; 18(5):e1009782. PubMed ID: 35604932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
